IP Library › Patent Application 15047705
Patent Application
App. No. 15/047,705

Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/047,705
Abstract

The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

Claims (9)

1 - 20 . (canceled)

21 . A method of treating a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury.

22 . A method of slowing the progression of a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury.

23 . The method of claim 21 , wherein the first compound and the second compound are associated with Tau or alpha-Synuclein.

24 . The method of claim 22 , wherein the first compound and the second compound are associated with Tau or alpha-Synuclein.

25 . The method of claim 23 , wherein the compound associated with Tau or alpha-Synuclein is an inhibitor of tau protein aggregation.

26 . The method of claim 25 , wherein the inhibitor of tau protein aggregation is methylthioninium chloride.

27 . The method of claim 24 , wherein the compound associated with Tau or alpha-Synuclein is an inhibitor of tau protein aggregation.

28 . The method of claim 27 , wherein the inhibitor of tau protein aggregation is methylthioninium chloride.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2016
From: ELMALEH, DAVID R.
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 038996/0780 →